Cruzado 2015.

Methods	Study design: parallel RCT Duration of study: not reported Duration of follow‐up: 12 months
Participants	Country: Spain Setting: multicentre Inclusion criteria: kidney transplant recipients with persistent hyperparathyroidism > 6 months post transplant (eGFR > 30 mL/min, iPTH > 15 pmol/L, serum calcium > 2.63 mmol/L, and serum phosphate <1.2 mmol/L) Number: treatment group (15); control group (15) Mean age ± SD (years): treatment group (55.0 ± 13.6); control group (53.0 ± 11.8) Sex (M/F): treatment group (7/8); control group (6/9) Exclusion criteria: not reported
Interventions	Treatment group Cinacalcet (oral): 30mg daily (titrating up to 60 mg daily) Control group Subtotal parathyroidectomy Co‐interventions Not reported
Outcomes	Primary outcome: achievement of normocalcaemia Level of iPTH, serum phosphate Kidney function (eGFR) BMD Vascular calcification Adverse events of medications
Notes	Funding source: Supported by Spanish Government Instituto de Salud Carlos III (ISCIII) Grants EC08/00237 and INT13/00126
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study between medical and surgical treatments
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	Low risk	Reporting of all anticipated patient‐level outcomes including adverse events
Other bias	Low risk	Study appears free of other biases